Can we make smart choices between ols and contaminated IV methods?

Health Economics (United Kingdom)

Volumn 23, Issue 4, 2014, Pages 462-472

  Basu, Anirban ^a,b   Chan, Kwun Chuen Gary ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

bias; contamination; diagnostic; instrumental variable; OLS

Indexed keywords

GENERIC DRUG; OLANZAPINE; PRESCRIPTION DRUG; RISPERIDONE;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER PROGRAM; DIAGNOSTIC PROCEDURE; HOSPITALIZATION; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; NORMAL DISTRIBUTION; ORDINARY LEAST SQUARE; PRIORITY JOURNAL; SAMPLING ERROR; SCHIZOPHRENIA; SIMULATION; STATISTICAL ANALYSIS; METHODOLOGY; PROCEDURES; REGRESSION ANALYSIS; STATISTICAL BIAS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); DATA INTERPRETATION, STATISTICAL; HUMANS; LEAST-SQUARES ANALYSIS; MODELS, ECONOMETRIC; MODELS, STATISTICAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RESEARCH DESIGN;

EID: 84904243116     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.2926     Document Type: Article

References (15)

1. Altonji JG, Elder TE, Taber CR,. 2005. Selection on observed and unobserved variables: assessing the effectiveness of catholic schools. Journal of Political Economy 113 (1): 151-184.
2. Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R,. 2012. Incorporating patient heterogeneity into comparative effectiveness research: evidence from schizophrenia. Mimeo, University of Washington.
3. Bound J, Jaeger DA, Baker RM,. 1995. Problems with instrumental variable estimation when correlation between the instruments and the endogenous explanatory variable in weak. Journal of the American Statistical Association 90 (430): 443-450.
4. Brookhart MA, Schneeweiss S,. 2007. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. International Journal of Biostatistics 3 (1): 14.
5. Crown WH,., Henk HJ, Vanness DJ,. 2011. Some cautions on the use of instrumental variables estimators in outcomes research: How bias in instrumental variable estimators is affected by instrument strength, instrument contamination, and sample size. Value in Health 14 (8): 1078-1084.
6. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A,. 2008. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophremia. PharmacoEconomics 18 (6): 567-79.
7. Lieberman JA, Stroup SS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, and the CATIE Investigators. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 353 (12): 1209-23.
8. Murray MP,. 2006. Avoiding invalid instruments and coping with weak instruments. Journal of Economic Perspectives 20: 111-132.
9. Newman TB, Vittinghoff E, McCullogh CE,. 2012. Efficacy of phototherapy for newborns with hyperbilirubinemia: a cautionary example of an instrumental variable. Medical Decision Making 32 (1): 83-92.
10. Penrod JD, Goldstein NE, Deb P,. 2009. When and how to use instrumental variable in palliative care research. Journal of Palliative Medicine 12 (5): 471-474.
11. Staiger D, Stock JH,. 1997. Instrumental variable regressions with weak instruments. Econometrica 65 (3): 557-586.
12. Stock JH, Trebbi F,. 2003. Who invented instrumental variable regression? Journal of Economic Perspectives 17 (3): 177-194.
13. Terza JV, Basu A, Rathouz PJ,. 2008. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. Journal of Health Economics 27 (3): 531-43.
14. Volavka J, Czobor P, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA,. 2002. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American Journal of Psychiatry 159: 255-262.
15. Zhao Z,. 2004. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia. Current Med Research Opinion 20 (7): 1039-48.